迪丽胡玛尔·扎衣尔,张斌,朱彬,田进,黄红明,张诗雨,王俊忠,郑昕,王宝菊

• 1:华中科技大学同济医学院附属协和医院感染性疾病科

摘要(Abstract)：

发热伴血小板减少综合征（severe fever with thrombocytopenia syndrome,SFTS）是由发热伴血小板减少综合征病毒（severe fever with thrombocytopenia syndrome virus,SFTSV），又称大别班达病毒（Dabie bandavirus,DBV）感染所致的急性蜱媒传染病。SFTSV能够影响天然免疫和获得性免疫中的多种免疫细胞，通过细胞因子和趋化因子的释放，使机体产生发热、血小板减少、白细胞减少、器官功能损害等，甚至导致多器官衰竭而造成患者死亡。尽管目前临床上暂无针对SFTSV的具有确切疗效的抗病毒药，但积极的支持对症治疗仍能挽救大部分SFTS患者的生命。为进一步了解SFTS，并探讨有效的SFTS诊疗手段，本文针对其发病机制及最新诊疗进展予以综述。

关键词(KeyWords)： 发热伴血小板减少综合征;发热伴血小板减少综合征病毒;新型布尼亚病毒;大别班达病毒;发病机制;治疗

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划（2021YFC2301803,2022YFC2305101）;; 湖北省自然科学基金项目（创新群体项目）（2022CFA010）

作者(Author): 迪丽胡玛尔·扎衣尔,张斌,朱彬,田进,黄红明,张诗雨,王俊忠,郑昕,王宝菊

DOI: 10.16505/j.2095-0136.2024.2013

参考文献(References)：

• [1] LI H, LU Q B, XING B, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17:a prospective observational study[J]. Lancet Infect Dis, 2018, 18(10):1127-1137. DOI:10.1016/S1473-3099(18)30293-7.
• [2]韩常新，孙艾军，蒲春文，等.新型布尼亚病毒感染致发热伴血小板减少综合征的流行病学特征及预后影响指标分析[J].中华医院感染学杂志，2019, 29(2):171-174,187. DOI:10.11816/cn.ni.2019-180685.HAN C X, SUN A J, PU C W, et al. Epidemiological characteristics of severe fever with thrombocytopenia syndrome caused by novel bunyavirus infection and influencing factors for prognosis[J]. Zhonghua Yiyuan Ganranxue Zazhi,2019, 29(2):171-174, 187. DOI:10.11816/cn.ni.2019-180685.
• [3] TANG X, WU W, WANG H, et al. Human-to-human transmission of severe fever with thrombocytopenia syndrome bunyavirus through contact with infectious blood[J]. J Infect Dis, 2013, 207(5):736-739. DOI:10.1093/infdis/jis748.
• [4] GUO C T, LU Q B, DING S J, et al. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome(SFTS)in China:an integrated data analysis[J]. Epidemiol Infect, 2016, 144(6):1345-1354. DOI:10.1017/S0950268815002678.
• [5] KUHN J H, ADKINS S, ALIOTO D, et al. 2020 taxonomic update for phylum Negarnaviricota(Riboviria:Orthornavirae), including the large orders Bunyavirales and Mononegavirales[J]. Arch Virol, 2022, 167(12):2857-2906. DOI:10.1007/s00705-020-04731-2.
• [6] ZHOU C M, YU X J. Unraveling the underlying interaction mechanism between Dabie bandavirus and innate immune response[J]. Front Immunol, 2021, 12:676861. DOI:10.3389/fimmu.2021.676861.
• [7] SONG P, ZHENG N, ZHANG L, et al. Down regulation of interferon-β and inhibition of TLR3 expression are associated with fatal outcome of severe fever with thrombocytopenia syndrome[J]. Sci Rep, 2017, 7(1):6532. DOI:10.1038/s41598-017-06921-6.
• [8] DENG B, ZHANG S, GENG Y, et al. Cytokine and chemokine levels in patients with severe fever with thrombocytopenia syndrome virus[J]. Plos One, 2012, 7(7):e41365. DOI:10.1371/journal.pone.0041365.
• [9] DING Y P, LIANG M F, YE J B, et al. Prognostic value of clinical and immunological markers in acute phase of SFTS virus infection[J]. Clin Microbiol Infect, 2014, 20(11):O870-O878. DOI:10.1111/1469-0691.12636.
• [10] PARK A, PARK S J, JUNG K L, et al. Molecular signatures of inflammatory profile and B-cell function in patients with severe fever with thrombocytopenia syndrome[J]. mBio,2021, 12(1):e02583-20. DOI:10.1128/mBio.02583-20.
• [11] HE Z, WANG B, LI Y, et al. Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome[J]. J Med Virol, 2021, 93(8):4704-4713. DOI:10.1002/jmv.26877.
• [12] CARTY M, GUY C, BOWIE A G. Detection of viral infections by innate immunity[J]. Biochem Pharmacol, 2021,183:114316. DOI:10.1016/j.bcp.2020.114316.
• [13] CHOW K T, GALE M, LOO Y M. RIG-I and other RNA sensors in antiviral immunity[J]. Annu Rev Immunol,2018, 36:667-694. DOI:10.1146/annurev-immunol-042617-053309.
• [14] LIU B Y, YU X J, ZHOU C M. SAFA initiates innate immunity against cytoplasmic RNA virus SFTSV infection[J]. Plos Pathog, 2021, 17(11):e1010070. DOI:10.1371/journal.ppat.1010070.
• [15] NING Y J, FENG K, MIN Y Q, et al. Disruption of type I interferon signaling by the nonstructural protein of severe fever with thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies[J]. J Virol, 2015, 89(8):4227-4236. DOI:10.1128/JVI.00154-15.
• [16] KITAGAWA Y, SAKAI M, SHIMOJIMA M, et al. Nonstructural protein of severe fever with thrombocytopenia syndrome phlebovirus targets STAT2 and not STAT1 to inhibit type I interferon-stimulated JAK-STAT signaling[J].Microbes Infect, 2018, 20(6):360-368. DOI:10.1016/j.micinf.2018.05.007.
• [17] CHAUDHARY V, ZHANG S, YUEN K S, et al. Suppression of typeⅠand typeⅢIFN signalling by NSs protein of severe fever with thrombocytopenia syndrome virus through inhibition of STAT1 phosphorylation and activation[J]. J Gen Virol, 2015, 96(11):3204-3211. DOI:10.1099/jgv.0.000280.
• [18] PENG C, WANG H, ZHANG W, et al. Decreased monocyte subsets and TLR4-mediated functions in patients with acute severe fever with thrombocytopenia syndrome(SFTS)[J]. Int J Infect Dis, 2016, 43:37-42. DOI:10.1016/j.ijid.2015.12.009.
• [19] LU Q B, CUI N, HU J G, et al. Characterization of immunological responses in patients with severe fever with thrombocytopenia syndrome:a cohort study in China[J]. Vaccine, 2015, 33(10):1250-1255. DOI:10.1016/j. vaccine.2015.01.051.
• [20] LI M, XIONG Y, LI M, et al. Depletion but activation of CD56dimCD16+NK cells in acute infection with severe fever with thrombocytopenia syndrome virus[J]. Virol Sin,2020, 35(5):588-598. DOI:10.1007/s12250-020-00224-3.
• [21] KABELITZ D. Gamma delta t cells(γδ T Cells)in health and disease:in memory of professor Wendy Havran[J].Cells, 2020, 9(12). 2564. DOI:10.3390/cells9122564.
• [22] XU W, LI X K, LU Q B, et al. Association between peripheral γδ T cell subsets and disease progression of severe fever with thrombocytopenia syndrome virus infection[J]. Pathog Dis, 2017, 75(7). DOI:10.1093/femspd/ftx086.
• [23] ZHANG W, LI M, XIONG S, et al. Decreased myeloid dendritic cells indicate a poor prognosis in patients with severe fever with thrombocytopenia syndrome[J]. Int J Infect Dis, 2017, 54:113-120. DOI:10.1016/j.ijid.2016.11.418.
• [24] SUN L, HU Y, NIYONSABA A, et al. Detection and evaluation of immunofunction of patients with severe fever with thrombocytopenia syndrome[J]. Clin Exp Med,2014, 14(4):389-395. DOI:10.1007/s10238-013-0259-0.
• [25] LIU J, WANG L, FENG Z, et al. Dynamic changes of laboratory parameters and peripheral blood lymphocyte subsets in severe fever with thrombocytopenia syndrome patients[J]. Int J Infect Dis, 2017, 58:45-51. DOI:10.1016/j.ijid.2017.02.017.
• [26] LI M M, ZHANG W J, WENG X F, et al. CD4 T cell loss and Th2 and Th17 bias are associated with the severity of severe fever with thrombocytopenia syndrome(SFTS)[J]. Clin Immunol, 2018, 195:8-17. DOI:10.1016/j.clim.2018.07.009.
• [27] LI M M, ZHANG W J, LIU J, et al. Dynamic changes in the immunological characteristics of T lymphocytes in surviving patients with severe fever with thrombocytopenia syndrome(SFTS)[J]. Int J Infect Dis, 2018, 70:72-80.DOI:10.1016/j.ijid.2018.03.010.
• [28] LI Y H, HUANG W W, HE W Q, et al. Longitudinal analysis of immunocyte responses and inflammatory cytokine profiles in SFTSV-infected rhesus macaques[J]. Front Immunol, 2023, 14:1143796. DOI:10.3389/fimmu.2023.1143796.
• [29] ZONG L, YANG F, LIU S, et al. CD8(+)T cells mediate antiviral response in severe fever with thrombocytopenia syndrome[J]. Faseb J, 2023, 37(1):e22722. DOI:10.1096/fj.202201343RR.
• [30] SONG L, ZHAO Y, WANG G, et al. Investigation of predictors for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome[J]. Sci Rep,2023, 13(1):1538. DOI:10.1038/s41598-023-28851-2.
• [31] LI X K, LU Q B, CHEN W W, et al. Arginine deficiency is involved in thrombocytopenia and immunosuppression in severe fever with thrombocytopenia syndrome[J]. Sci Transl Med, 2018, 10(459):eaat4162. DOI:10.1126/scitranslmed.aat4162.
• [32] TAKAHASHI T, SANO K, SUZUKI T, et al. Virusinfected peripheral blood plasmablasts in a patient with severe fever with thrombocytopenia syndrome[J]. Int J Hematol, 2021, 113(3):436-440. DOI:10.1007/s12185-020-03040-3.
• [33] WADA Y, MIYAMOTO S, IIDA S, et al. Propagation of activated B cells by in vitro severe fever with thrombocytopenia syndrome virus infection of human peripheral blood mononuclear cells[J]. J Infect Dis, 2022, 225(2):269-281.DOI:10.1093/infdis/jiab343.
• [34] WADA T, IWATA Y, KAMIKAWA Y, et al. Peripheral blood plasmacytosis in severe fever with thrombocytopenia syndrome[J]. Jpn J Infect Dis, 2017, 70(4):470-471.DOI:10.7883/yoken.JJID.2016.575.
• [35] TAKAHASHI T, SUZUKI T, HIROSHIGE S, et al.Transient appearance of plasmablasts in the peripheral blood of Japanese patients with severe fever with thrombocytopenia syndrome[J]. J Infect Dis, 2019, 220(1):23-27. DOI:10.1093/infdis/jiz054.
• [36] SONG P, ZHENG N, LIU Y, et al. Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection[J]. Nat Commun, 2018, 9(1):3328. DOI:10.1038/s41467-018-05746-9.
• [37] SUZUKI T, SATO Y, SANO K, et al. Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections[J]. J Clin Invest, 2020, 130(2):799-812. DOI:10.1172/JCI129171.
• [38] ARAB-BAFRANI Z, JABBARI A, MOSTAKHDEM HASHEMI M, et al. Identification of the crucial parameters regarding the efficacy of ribavirin therapy in Crimean-Congo haemorrhagic fever(CCHF)patients:a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2019, 74(12):3432-3439. DOI:10.1093/jac/dkz328.
• [39] SHIMOJIMA M, FUKUSHI S, TANI H, et al. Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro[J]. Jpn J Infect Dis, 2014, 67(6):423-427. DOI:10.7883/yoken.67.423.
• [40] ZHANG Y, MIAO W, XU Y, et al. Severe fever with thrombocytopenia syndrome in Hefei:clinical features, risk factors, and ribavirin therapeutic efficacy[J]. J Med Virol,2021, 93(6):3516-3523. DOI:10.1002/jmv.26544.
• [41] KOWDLEY K V. Hematologic side effects of interferon and ribavirin therapy[J]. J Clin Gastroenterol, 2005, 39(1 Suppl):S3-S8. DOI:10.1097/01.mcg.0000145494.76305.11
• [42] SAKRAN R, FRISCH A, ELIAS A, et al. Acute and severe ribavirin-associated hyperuricemia and acute kidney injury:an under recognized adverse effect[J]. Am J Health Syst Pharm, 2021, 78(9):794-799. DOI:10.1093/ajhp/zxab043.
• [43] FURUTA Y, TAKAHASHI K, FUKUDA Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705[J]. Antimicrob Agents Chemother, 2002, 46(4):977-981. DOI:10.1128/AAC.46.4.977-981.2002.
• [44] TANI H, KOMENO T, FUKUMA A, et al. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model:doseefficacy studies upon oral administration[J]. Plos One,2018, 13(10):e0206416. DOI:10.1371/journal.pone.0206416.
• [45] TANI H, FUKUMA A, FUKUSHI S, et al. Efficacy of T-705(Favipiravir)in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus[J]. mSphere, 2016, 1(1):e00061-15. DOI:10.1128/mSphere.00061-15.
• [46] GOWEN B B, WESTOVER J B, MIAO J, et al. Modeling severe fever with thrombocytopenia syndrome virus infection in golden syrian hamsters:importance of STAT2 in preventing disease and effective treatment with favipiravir[J]. J Virol,2017, 91(3):e01942-16. DOI:10.1128/JVI.01942-16.
• [47] LI H, JIANG X M, CUI N, et al. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome[J]. Signal Transduct Target Ther,2021, 6(1):145. DOI:10.1038/s41392-021-00541-3.
• [48] YUAN Y, LU Q B, YAO W S, et al. Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome[J]. EBioMedicine,2021, 72:103591. DOI:10.1016/j.ebiom.2021.103591.
• [49] SUEMORI K, SAIJO M, YAMANAKA A, et al. A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome[J]. Plos Negl Trop Dis, 2021, 15(2):e0009103. DOI:10.1371/journal.pntd.0009103.
• [50] LEPORRIER M. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia[J]. Hematol J,2004, 5 Suppl 1:S10. DOI:10.1038/sj.thj.6200387.
• [51] GAO C, WEN C, LI Z, et al. Fludarabine inhibits infection of Zika virus, SFTS phlebovirus, and enterovirus A71[J].Viruses, 2021, 13(5):774-786. DOI:DOI:10.3390/v13050774.
• [52] DING X, HERZLICH A A, BISHOP R, et al. Ocular toxicity of fludarabine:a purine analog[J]. Expert Rev Ophthalmol, 2008, 3(1):97-109. DOI:10.1586/17469899.3.1.97.
• [53] LAVANYA M, CUEVAS C D, THOMAS M, et al.siRNA screen for genes that affect Junín virus entry uncovers voltage-gated calcium channels as a therapeutic target[J].Sci Transl Med, 2013, 5(204):204ra131. DOI:10.1126/scitranslmed.3006827.
• [54] GEHRING G, ROHRMANN K, ATENCHONG N, et al.The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry[J]. J Antimicrob Chemother, 2014, 69(8):2123-2131. DOI:10.1093/jac/dku091.
• [55] SAKURAI Y, KOLOKOLTSOV A A, CHEN C C, et al.Ebola virus. two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment[J]. Science, 2015, 347(6225):995-998. DOI:10.1126/science.1258758.
• [56] LI H, ZHANG L K, LI S F, et al. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus(SFTSV)related fatality[J]. Cell Res, 2019, 29(9):739-753. DOI:10.1038/s41422-019-0214-z.
• [57] BOONYASUPPAYAKORN S, REICHERT E D, MANZANO M, et al. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity[J]. Antiviral Res,2014, 106:125-134. DOI:10.1016/j.antiviral.2014.03.014.
• [58] GIGNOUX E, AZMAN A S, DE SMET M, et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease[J]. N Engl J Med, 2016, 374(1):23-32. DOI:10.1056/NEJMoa1504605.
• [59] BABA M, TOYAMA M, SAKAKIBARA N, et al. Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors[J]. Antivir Chem Chemother, 2017, 25(3):83-89. DOI:10.1177/2040206617740303.
• [60] URATA S, UNO Y, KUROSAKI Y, et al. The cholesterol, fatty acid and triglyceride synthesis pathways regulated by site 1 protease(S1P)are required for efficient replication of severe fever with thrombocytopenia syndrome virus[J]. Biochem Biophys Res Commun, 2018, 503(2):631-636. DOI:10.1016/j.bbrc.2018.06.053.
• [61] LIU X, ZHANG Y, XU X, et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A(H7N9):a cohort study[J]. Ther Apher Dial, 2015, 19(2):178-184. DOI:10.1111/1744-9987.12240.
• [62] OH W S, HEO S T, KIM S H, et al. Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome[J]. Int J Infect Dis, 2014, 18:84-86.DOI:10.1016/j.ijid.2013.08.011.
• [63] KIM U J, KIM D M, AHN J H, et al. Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid[J]. Antivir Ther,2016, 21(7):637-640. DOI:10.3851/IMP3036.
• [64] NAKAMURA S, AZUMA M, MARUHASHI T, et al.Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome[J]. J Infect Chemother, 2018, 24(5):389-392. DOI:10.1016/j.jiac.2017.11.004.
• [65] HIRAKI T, YOSHIMITSU M, SUZUKI T, et al. Two autopsy cases of severe fever with thrombocytopenia syndrome(SFTS)in Japan:a pathognomonic histological feature and unique complication of SFTS[J]. Pathol Int,2014, 64(11):569-575. DOI:10.1111/pin.12207.
• [66] KATO H, YAMAGISHI T, SHIMADA T, et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013—2014[J]. Plos One,2016, 11(10):e0165207. DOI:10.1371/journal.pone.0165207.
• [67] JUNG S I, KIM Y E, YUN N R, et al. Effects of steroid therapy in patients with severe fever with thrombocytopenia syndrome:a multicenter clinical cohort study[J]. Plos Negl Trop Dis, 2021, 15(2):e0009128. DOI:10.1371/journal.pntd.0009128.
• [68] DENIC S, JANBEIH J, NAIR S, et al. Acute thrombocytopenia, leucopenia, and multiorgan dysfunction:the first case of SFTS bunyavirus outside China?[J]. Case Rep Infect Dis, 2011, 2011:204056. DOI:10.1155/2011/204056.
• [69] LIU Y, TONG H, HE F, et al. Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications[J]. Front Immunol, 2023, 14:1118039. DOI:10.3389/fimmu.2023.1118039.

文章评论(Comment)：